Search

Your search keyword '"Wu, Jenny Qun"' showing total 8 results
Start Over Author "Wu, Jenny Qun"
8 results on '"Wu, Jenny Qun"'

1. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

Author

Loi, Sherene, Salgado, Roberto, Curigliano, Giuseppe, Romero Díaz, Roberto Iván, Delaloge, Suzette, Rojas García, Carlos Ignacio, Kok, Marleen, Saura, Cristina, Harbeck, Nadia, Mittendorf, Elizabeth A., Yardley, Denise A., Suárez Zaizar, Alberto, Caminos, Facundo Rufino, Ungureanu, Andrei, Reinoso-Toledo, Joaquin G., Guarneri, Valentina, Egle, Daniel, Ades, Felipe, Pacius, Misena, Chhibber, Aparna, Chandra, Rajalakshmi, Nathani, Raheel, Spires, Thomas, Wu, Jenny Qun, Pusztai, Lajos, and McArthur, Heather

Published
2025
Full Text
View/download PDF

2. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Author

Kater, Arnon P, Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D’Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R, Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, and Seymour, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Lymphoma, Genetics, Rare Diseases, Good Health and Well Being, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Bridged Bicyclo Compounds, Heterocyclic, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Karyopherins, Leukemia, Lymphocytic, Chronic, B-Cell, Mutation, Progression-Free Survival, Proto-Oncogene Proteins B-raf, Receptor, Notch1, Receptors, Cytoplasmic and Nuclear, Rituximab, Sulfonamides, Treatment Outcome, Tumor Suppressor Protein p53, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeIn previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics.Patients and methodsPatients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed.ResultsOf 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT.ConclusionEfficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

Published
2020

3. Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx)

Author

Seymour, John F., primary, Wu, Jenny Qun, additional, Popovic, Relja, additional, Eichhorst, Barbara, additional, Hillmen, Peter, additional, Kipps, Thomas J., additional, Langerak, Anton W., additional, Owen, Carolyn, additional, Dubois, Julie, additional, Mellink, Clemens, additional, Van Der Kevie-Kersemaekers, Anne-Marie, additional, Dunbar, Fengjiao, additional, Jiang, Yanwen, additional, Chyla, Brenda, additional, Boyer, Michelle, additional, Thadani-Mulero, Maria, additional, Lefebure, Marcus, additional, Harrup, Rosemary, additional, and Kater, Arnon P., additional

Published
2021
Full Text
View/download PDF

4. Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

Author

Kater, Arnon P., primary, Lu, Tong, additional, Langerak, Anton W., additional, Mellink, Clemens, additional, Chyla, Brenda, additional, Wu, Jenny Qun, additional, Boyer, Michelle, additional, Lefebure, Marcus, additional, Jiang, Yanwen, additional, and Seymour, John F., additional

Published
2021
Full Text
View/download PDF

5. Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Author

Soumerai, Jacob D., primary, Mato, Anthony R., additional, Dogan, Ahmet, additional, Seshan, Venkatraman, additional, Joffe, Erel, additional, Flaherty, Kelsey, additional, Carter, Jason, additional, Hochberg, Ephraim P, additional, Barnes, Jeffrey A, additional, Hamilton, Audrey, additional, Abramson, Jeremy S., additional, Batlevi, Connie Lee, additional, Matasar, Matthew J., additional, Noy, Ariela, additional, Owens, Colette, additional, Palomba, M. Lia, additional, Kumar, Anita, additional, Takvorian, Tak, additional, Ni, Ai, additional, Choma, Morgan, additional, Friedman, Chaya, additional, Chadha, Puja, additional, Simkins, Elizabeth, additional, Ruiters, Jade, additional, Sechio, Sidney, additional, Portman, Daneal, additional, Nolet, Natascha, additional, Mahajan, Neena, additional, Martignetti, Rosalba, additional, Mi, Joanna, additional, Scorsune, Krista J, additional, Lynch, Julia M, additional, McGree, Brianne, additional, Hughes, Stephanie Y, additional, Grieve, Clare, additional, Roeker, Lindsey E., additional, Thompson, Meghan C., additional, Johnson, P. Connor, additional, Roshal, Mikhail, additional, Huang, Jane, additional, Biondo, Juliana M.L., additional, Wu, Jenny Qun, additional, Jacob, Allison P., additional, Abdel-Wahab, Omar, additional, and Zelenetz, Andrew D., additional

Published
2021
Full Text
View/download PDF

6. Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

Author

Gopal, Ajay K., Armand, Philippe, Neelapu, Sattva S., Bartlett, Nancy L., Spurgeon, Stephen E., Kuruvilla, John, Savage, Kerry J., Leonard, John P., Gelb, Arnold B., Ahmed, Nasir, Dong, Shiqi, Bathena, Sai Praneeth, Suryawanshi, Rasika, Wu, Jenny Qun, Wang, Sheen, and Gladstone, Douglas E.

Abstract

•Nivolumab plus relatlimab was overall safe, tolerable, and manageable with no unexpected safety signals or treatment-related deaths.•The combination of nivolumab and relatlimab demonstrated antitumor activity in the subset of immune checkpoint naïve patients with HL.

Published
2025
Full Text
View/download PDF

7. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Author

Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, Seymour, John F., Kater, Arnon P., Wu, Jenny Qun, Kipps, Thomas, Eichhorst, Barbara, Hillmen, Peter, D'Rozario, James, Assouline, Sarit, Owen, Carolyn, Robak, Tadeusz, de la Serna, Javier, Jaeger, Ulrich, Cartron, Guillaume, Montillo, Marco, Dubois, Julie, Eldering, Eric, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Kim, Su Young, Chyla, Brenda, Punnoose, Elizabeth, Bolen, Christopher R., Assaf, Zoe June, Jiang, Yanwen, Wang, Jue, Lefebure, Marcus, Boyer, Michelle, Humphrey, Kathryn, and Seymour, John F.

Abstract

PURPOSEIn previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic characteristics.PATIENTS AND METHODSPatients with CLL were randomly assigned to 2 years of venetoclax (VenR for the first six cycles) or six cycles of BR. PFS, overall survival (OS), peripheral-blood minimal residual disease (MRD) status, genomic complexity (GC), and gene mutations were assessed.RESULTSOf 389 patients, 194 were assigned to VenR and 195 to BR. Four-year PFS and OS rates were higher with VenR than BR, at 57.3% and 4.6% (hazard ratio [HR], 0.19; 95% CI, 0.14 to 0.25), and 85.3% and 66.8% (HR, 0.41; 95% CI, 0.26 to 0.65), respectively. Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior PFS compared with low MRD positivity (HR, 0.50) and high MRD positivity (HR, 0.15). Patients in the VenR arm who received ibrutinib as their first therapy after progression (n = 12) had a reported response rate of 100% (10 of 10 evaluable patients); patients subsequently treated with a venetoclax-based regimen (n = 14) had a reported response rate of 55% (six of 11 evaluable patients). With VenR, the uMRD rate at end of treatment (EOT) was lower in patients with GC than in those without GC (P = .042); higher GC was associated with shorter PFS. Higher MRD positivity rates were seen with BIRC3 and BRAF mutations at EOCT and with TP53, NOTCH1, XPO1, and BRAF mutations at EOT.CONCLUSIONEfficacy benefits with fixed-duration VenR are sustained and particularly durable in patients who achieve uMRD. Salvage therapy with ibrutinib after VenR achieved high response rates. Genetic mutations and GC affected MRD rates and PFS.

Published
2020

8. Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Author

Kater, Arnon P, primary, Wu, Jenny Qun, primary, Dubois, Julie, primary, Bolen, Christopher R, primary, Assaf, Zoe J, primary, Hillmen, Peter, primary, Eichhorst, Barbara F., primary, Eldering, Eric F, primary, Kipps, Thomas J., primary, Langerak, Anton W, primary, Mellink, Clemens, primary, Van Der Kevie-Kersemaekers, Anne-Marie, primary, Owen, Carolyn, primary, Chyla, Brenda J, primary, Punnoose, Elizabeth A, primary, Wang, Jue, primary, Lefebure, Marcus, primary, Boyer, Michelle, primary, Humphrey, Kathryn, primary, Jiang, Yanwen, primary, and Seymour, John F., primary

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results